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ABSTRACT
ESTABLISHMENT OF A RAPID MUTATION DETECTION 
TECHNIQUE FOR SCREENING BRCAl AND  BRCA2 
GENES
EMRE ÓKTEM
M S. Thesis in Molecular Biology and Genetics 
Superxdsor: Dr. Tayfim Ozgelik 
August 1997, 60 pages
People bearing germline mutations in either BRCAl or BRCA2 genes are more 
prone to breast cancer than other people. These two recently identified genes 
account for nearly 90% o f the hereditary cancer cases. This number corresponds 
approximately to 100,000 women each year in Turkey. The individuals who carry 
these mutations are at high risk and characterizing these mutations will be helpful 
for providing them genetic counseling. This includes the estimation of risk for 
both the individual and his/her progeny. In addition, discovering the mutations is 
an important step in finding out the iunctions of these genes, which will give 
insights about how breast cancer is occurring
In this study, we have established an easy and rapid mutation detection strategy; 
heteroduplex analysis, and tested its efficiency in 15 hereditary breast cancer 
patients. These patients have been screened for the entire exon 11 of BRCAl, 
which is 50% o f the entire coding region. In addition, half of the exon 11 of 
BRCA2, which is roughly one fourth of the coding region was examined in 10 
patients. As yet, no mutation in the Turkish patients have been encountered 
These results exclude exon 11 o f the BRCAl gene and part o f exon 11 of the 
BRCA2 gene for nucleotide deletions and insertions as the cause of hereditary 
breast cancer in Turkey. In order to verily the efficiency o f the technique, we have 
also screened four French hereditary breast cancer patients with previously 
characterized BRCAl mutations in exon 11, and confirmed the presence o f the 
mutations in the majority o f the cases With the technique, firmly established in 
our laboratory, we plan to analyze the remaining coding regions o f the BRCAl 
and BRCA2 genes in our patient samples and in additional patients.
Ill
ÖZET
BRCAl VE BRCA2 GENLERİNİN İNCELENMESİ İÇİN 
ÇABUK BİR MUTASYON TANI YÖNTEMİNİN GELİŞTİRİLMESİ
EMRE ÖKTEM
Yüksek lisans tezi, Moleküler Biyoloji ve Genetik Bölümü 
Tez Yöneticisi; Assoc. Prof. Dr. Tayfun Özçelik 
Ağustos 1997, 60 sayfa.
BRCAl ve BRCA2 genlerini kalıtan insanlann diğer insanlara göre meme 
kanserine yakalanma riskleri daha yüksektir. Yeni tammlanmış olan bu iki gen, 
kalıtsal meme kanserlerinin yaklaşık yüzde doksamndan sorumludur. Bu rakam 
Türkiye için yaklaşık olarak 100,000 meme kanserli kadın demektir. Bu genlerin 
mutasyona uğramç formlannı taşıyan insanlar, meme kanserine yakalanma riski 
altındadırlar. Bu genlerdeki mutasyonlann bulunması risk altındaki kişilere ve 
yakın akrabalanna genetik danışma verme açısından çok önemlidir. Öte yandan, 
meme kanserinin oluşum aşamalanmn anlaşılmasında da söz konusu genlerin 
mutasyonlanmn ortaya çıkarılması büyük önem taşımaktadır.
Bu tez çalışması ile kolay ve çabuk bir mutasyon tarama yöntemi olan 
heterodupleks analizi laboratuvanmızda kullanıma geçirilmiş ve 15 kalıtsal meme 
kanserli hastanın mutasyonlan taranımştır. BRCAl geninin kodlanan kısmının 
yaklaşık yüzde ellisini oluşturan 11. eksonda mutasyon taraması yapılmıştır. Ek 
olarak, BRCA2 geninin kodlanan kısmımn yaklaşık dörtte birini içeren 11 
eksonun yansı da on hastada incelenmiştir. Bu sonuçlar, incelenen Türk 
hastalanndaki meme kanserinin, BRCAl geninin 11. eksonu veya BRCA2 geninin
11. aksonunun ilgili bölgesinde bulunan delesyon veya insersiyonlardan 
kaynaklanmadığını göstermektedir. Hetereodupleks analizi tekniğinin geçerliliği, 
Fransız meme kanserli hastalardan alınmış ve BRCAl geni 11. aksonunda 
mutasyonlan daha önce belirlenmiş dört DNA örneğinde bu mutasyonlann 
başanyla gösterilmesiyle kanıtlanmıştır. Laboratuvanmızda güvenilir bir şekilde 
kullanıma soktuğumuz bu teknikle BRCAl ve BRCA2 genlerinin diğer kodlayan 
bölgelerini mevcut ve yeni hastalarda araştırmak bir sonraki hedefimizdir.
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1. INTRODUCTION
Ankara, year 2004, a woman at the age o f 34 enters the building on the wall o f 
which is written “Genetic Counseling”. She wants to know her risk o f developing 
breast cancer. Because o f breast cancer her mother has lost one of her breasts, her 
aunt died at an early age and her grandfather bereaved them due to male breast 
cancer. She is aware o f the inherited forms o f cancer and wants to know the risk o f 
not only herself but also her two little children. She tells her story to the genetic 
counselor. “Either BRCAl, BRCA2 or BRCA3 ” he thinks, “ it is evidently a breast 
cancer family. Presence o f a male breast cancer patient increases the probability that 
this is a BRCA2 family, however we have to be sure o f the situation ”, “Would you 
please have these tests done?” requests the genetic counselor handling the 
prescription to the young woman, “ at the upper floor we have a genetic testing 
unit.” . At the unit, rapid mutation detection techniques are routinely being done. 
With reliable mutation screening techniques, a patient’s DNA is isolated from the 
blood and analyzed for the mutations in the genes BRCAl, BRCA2 and BRCA3 
which gives information about the presence o f familial breast cancer.
The aim o f my thesis is establishment o f a rapid mutation detection technique which 
is the first step o f realizing a scene like the one described above. The discovery o f 
the cancer predisposition genes lead to pretty accurate estimation o f cancer risk in 
individuals. The incidence o f the inherited form of breast cancer is 1 in every 200 
individuals. This increases the importance o f the mutation detection techniques 
which are currently the only way to reveal the people at risk.
After giving general information about cancer and its causes, the genes 
predisposing to breast cancer, BRCAl and BRCA2 will be focused on. Widely 
utilized mutation detection techniques will be elucidated, proceeding the results o f 
the survey done on 15 breast cancer patients using heteroduplex analysis.
THEORETICAL BACKGROUND
2.1. OF CELLS AND HUMAN BEINGS
The relation between each o f the 30 trillion cells o f a human body is similar to that 
o f a human being and his six billion counterparts. To live properly, the cells 
intercommunicate with each other by sending signals and receiving them They 
regulate their functions, size and maintain their location according to these 
signals[l]. In addition, they have a certain life cycle starting from each cell division. 
Decision to divide or stay at a certain point of the cell cycle to differentiate is given 
by the inherent mechanisms and regulated upon communicating with the cellular 
and environmental signals[2]. They stop growing at a certain size and stay at a 
particular location, respecting every other cell. Some may even commit suicide for 
the sake o f not harming the other cells[3]. The entire knowledge leading to the 
delicate machinery o f a cell is saved in its nucleus in the form o f DNA, whose 
functional units are named as genes. There are around 100,000 genes dispersed in 
the chromosomes lying inside the nucleus o f a human being and each encode for a 
protein that will perform a certain function. Some o f them carry out structural 
functions, some specialized functions and some are in charge o f maintaining the
integrity o f the cell[4]. Another group o f genes encode for proteins that mediate the 
communications; sending and receiving signals, thereby regulating the cell behavior 
and cell cycle according to these signals. These genes, which play a major part in 
developing cancer are collectively termed as proto-oncogenes and tumor 
suppressor genes[l]. These genes will be the topics o f the following sections.
2.2. WHAT IS CANCER?
Environment, even though it donates a cell its living conditions, may also pose 
problems by creating agents that can damage DNA. These agents vary from 
ultraviolet radiation coming from the sun, to the free radicals being formed from the 
food intaken. When a damage comes to the genes, a mutation might occur, which is 
a permanent change in the nucleotide sequence o f a gene. A mutation may occur in 
the genes called the proto-oncogenes and/or the tumor suppressor. Unless they are 
repaired by the mechanisms inside the nucleus[5], the cell or cells may begin to 
change their life-style and begin to follow their own agenda for reproduction 
disregarding the usual controls exerted from the cells in the vicinity. These cells 
may even migrate from the site they began, invading nearby tissues and forming 
masses at different sites of the body. These cells called cancer cells may form 
tumors which become more and more aggressive over time, and they become lethal 
when they disrupt the tissues and organs needed for the survival of the organism as 
hole[l]. Since any cell in the body might be transformed into a cancer cell, cancer is 
a collection o f about 100 diseases.
The first group o f genes that are discovered leading to cancer are the proto­
oncogenes. When mutated, proto-oncogenes can become carcinogenic oncogenes 
that drive excessive multiplication. The mutations may cause the proto-oncogene to 
yield too much o f its encoded growth-stimulatory protein or any overly active form 
o f it[6]. A mutation in one o f the alleles o f a proto-oncogene is enough to initiate 
carcinogenesis. Table 2-1 lists some o f the important proto-oncogenes and their 
functions:
2.2.1. ONCOGENES
I'able 2-1 Important oncogenes in human cancers (Adapted form reference 1).
ONCOGENES
denes fo r  growth factors or receptors
PDGF Codes for platelet derived growtli factor. Involved in glioma. 
erb-B Codes for the receptor of the epidermal growth factor. Involved in 
glioblastoma and breast cancer.
erb-B2 Codes for a growth factor receptor. Involved in thyroid cancer.
Genes fo r  cytoplasmic relays in stimulatory signaling pathways 
Ki-ras Involved in lung, ovarian, colon and pancreatic cancers.
N-ras Involved in leukemias.
Genes fo r  transcription factors that activate growth-promoting genes. 
c-mvc Involved in leukemias and breast, stomach and lung cancers.
N-mvc Involved in neuroblastoma and glioblastoma.
L-mvc Involved in lung cancer.
Genes fo r  other kinds o f molecules
Bcl-2 Codes for a protein that normally blocks cell suicide. Involved in follicular 
B-cell lymphoma.
Bcl-1 Codes for cyclin Dl, a stimulatory component of tlie cell cycle clock.
Involved in breast, neck and head cancers.
MDM2 Codes for an antagonist of tlie p53 tumor-suppressor protein. Involved in 
sarcomas and other cancers.
The second group discovered as a cause o f cancer is the tumor-suppressor genes. 
These genes usually encode for proteins that suppress the excessive growth o f a 
cell. To become malignant, cells must do more than overstimulate their growth- 
promoting machinery. They must also devise ways to evade or ignore braking 
signals issued by their normal neighbors in the tissue. Those braking signals are 
encoded by the tumor suppressor genes which are absent or inactive in many types 
o f cancer cells. For cancer to be initiated, both o f the alleles o f a tumor suppressor 
gene have to be impaired, since only one copy may carry out the adequate 
supressive function. Hereditary cancers occur due to the inheritance o f a mutated 
copy o f a tumor suppressor gene. For example, Li-Fraumeni syndrome occurs upon 
inheriting a gemline mutation o f the p53 gene, similarly, familial melanoma occurs 
as a result o f carrying a p i6 gene mutation in the germline. The only documented 
hereditary neoplasm that is not due to a tumor suppressor gene mutation is multiple 
endocrine neoplasia[ 1 ], which arises from germline mutations o f the RET 
oncogene. Very recently, Vogelstein and Kinzler[7] classified the tumor-suppressor 
genes depending on their function and their relative risk o f leading to cancer when 
mutated. The two classes are named as gatekeepers and caretakers. They will be 
discussed in the following section. Table 2-2 is a list o f important tumor-suppressor
2.2.2. TUMOR SUPPRESSOR GENES
genes.
Table 2-2 Important tumor suppressor genes in human cancers (Adapted from reference 1).
Genes fo r  proteins in the cytoplasm 
APC Involved in colon and stomach cancers.
DPC 4 Codes for a relay m olecule in a signaling pathway that inliibits cell division. 
Involved in pancreatic cancer.
NF-1 Codes for a protein tliat inhibits a stimulatory protein (Ras). Involved in 
neurofibroma and pheochromocytoma and m yeloid leukemia.
N F-2 Involved in meningioma and ependymoma and schwannoma.
Genes for proteins in the nucleus
M T S l Codes for tlie p l6  protein, a braking component o f  the cell cycle clock. 
Involves in a w ide range o f  cancers.
RB Codes for tlie pRB protein, a master brake o f  the cell cycle. Involved in 
retinoblastoma and bone, bladder, small cell lung and breast cancer. 
p53 Codes for the p53 protein, which can halt cell division and induce abnormal 
cells to kill themselves. Involved in a w ide range o f  cancers.
W T l Involved in W ilm s’ tumor o f  the kidney.
Genes for proteins whose cellular location and function is not yet clear 
B R C A l Involved in breast and ovarian cancers.
BRCA2 Involved in breast and pancreatic cancers.
VHL Involved in renal cancer.
2 2 3 GATEKEEPERS AND CARETAKERS
Genes that control the cellular proliferation directly are named as gatekeepers, 
while the genes that maintain the integrity of the genome are called the caretakers. 
Retinoblastoma(Rb) and p53 can be regarded as gatekeeper genes. Germline 
mutations o f gatekeepers lead directly to the development o f hereditary cancers. 
For example Li-Fraumeni Syndrome is due to p53 gene and familial retinoblastoma 
is due to Rb gene mutations. For tumor development both the maternal and the 
paternal copies must be altered[8]. Predisposed individuals have one copy mutated, 
so they need one additional somatic mutation to initiate neoplasi, which is called 
“loss o f heterozygosity” . A hereditary mutation in a gatekeeper gene increases the
risk o f an individual around 1000 times more than the general population. 
However, inactivation o f a caretaker doesn’t lead directly to the development o f 
cancer. Instead, inactivation leads to genetic instabilities in the genome resulting in 
increased mutation o f all genes, including the gatekeepers. An accelerated rate o f 
mutation is induced by the mutation o f a caretaker. Therefore, in dominantly 
inherited cancer-predisposition syndromes o f the caretaker type, somatic mutations 
that involve the gatekeepers are required to initiate cancer. So the risk becomes 5- 
50 fold greater than in the general population, which is quite low when compared 
to the inherited gatekeeper mutations. In addition, mutations in caretakers will not 
be expected to lead to sporadic cancers very often since both alleles o f the caretaker 
and in addition both alleles o f a gatekeeper should be inactivated for the initiation of 
neoplasia. The known caretaker genes are the NER (Nucleotide Excision Repair) 
genes[5], mismatch repair genes(HNPCC)[9] and ATM gene[5], which all play 
roles in DNA repair.
2.3. WHAT CAUSES CANCER?
Now comes the question, what triggers carcinogenesis ? The so-called carcinogens 
are either chemicals, physical effects or biological agents that are able to damage 
DNA. The top carcinogen seems to be the tobacco smoke which brings about 30% 
o f cancer deaths[l]. The only rival to tobacco as a cause o f cancer is diet. Animal 
fat in general, and red meat are associated with several cancers. Radiation, 
especially the ultraviolet B rays originating from the sun, cause more than 90% of
skin cancers. Some o f the chemicals that are used in the workplaces for special 
purposes are proven to be causes o f cancer. Among these chemicals; asbestos, 
benzene, formaldehyde and soot are examples. In addition to the chemicals, 
biological agents can also damage DNA. The most common cancer causing 
pathogens are the DNA viruses. Of these viruses papilloma viruses types 16 and 18, 
and the hepatitis B virus are the most important. The former viruses can lead to 
cancer o f the cervix, while the latter can cause liver cancer. The insult on the DNA 
caused by these agents targets generally the somatic cells and rarely the germline. In 
the latter cases when the gatekeeper and the caretaker genes are affected, the result 
becomes familal forms o f cancers.
2.4. FAMILIAL FORMS OF CANCER
2.4.1. GENERAL VIEW
As stated earlier, some people are one step closer to cancer than the others. People 
who have inherited one mutant copy o f a caretaker or a gatekeeper gene have 
higher probablity o f lifetime risk o f cancer[10]. Some o f the important familal 
cancers are hereditary non-polyposis colon cancer (HNPCC), familial 
breast/ovarían cancer, neurofibromatosis type 1, familal adenomatous polyposis 
(APC) and familial retinoblastoma. Examples o f the genes that lead to familial 
cancers and their incidence is shown in Table 2-3.
NAME
HNPCC
FAMILIAL BREAST/OVARIAN CANCER 
NEUROFIBROMATOSIS 1 
WILM’S TUMOR
FAMILIAL ADENOMATOUS POLYPOSIS
RETINOBLASTOMA
MULTIPLE ENDOCRINE NEOPLASIA 2
VON HIPPEL LINDAU
NEUROFIBROMATOSIS 2
BASAL CELL NERVOUS SYNDROME
LI-FRAUMENI
FAMILIAL MELANOMA
Table 2-3 Some familial forms of cancer
INCIDENCE GENES
1:200 MLH1,MSH2,PMS1,PMS2
1:300 BRCA1, BRCA2
1:3000 NF-1
1:8000 WT-1
1:10000 APC
1:20000 RBI
1:25000 RET
1:36000 VHL
1:37000 NF-2
1:56000 PTC
very rare p53
rare pi 6
Among these familial cancers, breast/ovarian cancer is o f special importance for us 
and therefore more information will be given in the following section.
2.5. FAMILIAL BREAST CANCER
2.5.1. CLINICAL CRITERIA
Breast cancer is the third most common tumor in the world after lung and colon 
cancers[l]. It is estimated that about one in ten women in the Western world develop 
cancer of the breast by the age of 70, and between 5% to 10% o f these cases are 
thought to result from a hereditary predisposition to the disease[10]. This number 
roughly represents 3 million breast cancer cases only this year in Turkey and about 
100,000 of these women develop the disease because of having inherited either o f 
the two recently discovered breast cancer genes in a mutated form. The first o f these 
genes was found by positional cloning in 1994[11]. It was given the
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name BRCAl, abbreviated form o f Breast Cancer Associated 1. The second gene, 
conceivably named as BRCA2, was cloned one year later[12]. These two genes 
account for nearly 90% o f the hereditary breast cancer cases[10].
2.5.2. THE GENES PREDISPOSING TO BREAST CANCER
2.5.2.1.BRCA1
The first gene that appeared in the familial breast cancer scene was BRCAl. It is 
linked to chromosome 17q21[13], and spans around 70kb o f genomic DNA. It has 
24 exons, where exons 1 and 4 are not transcribed. A protein o f 1863 amino acids 
is brought about upon the translation.
The DNA sequence o f BRCAl includes, an N-terminal ring domain, a negatively 
charged region in its C-terminus, and C-terminal sequences are partially 
homologous to yeast RAD9 and to a cloned p53 binding protein[10]. Mutations in 
the BRCAl gene represent a predisposing factor in nearly 45% of hereditary breast 
cancer cases and more than 80% o f hereditary ovarian cases[14, 15]. There is also 
an increased risk for BRCAl carriers to develop prostate cancer (3%) in males and 
colon cancer (4%) in males and females[16]. The average risk for developing breast 
or ovarian cancer for BRCAl carriers by age o f 70 years is 85% and 63%, 
respectively[17].
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2.5.2.2. BRCA2
Following linkage o f BRCAl to chromosome 17, it soon became clear that many 
breast cancer families failed to show linkage to this locus. Whereas the majority o f 
breast and ovarian cancer families were linked to BRCAl, less than 50% of breast 
site-specific cancer families showed linkage. So, non-BRCAl-linked families brought 
the gene BRCA2 to the scene, which is linked to chromosome 13ql2-13[12]. It has 
27 exons, making up a 10,348 bp mRNA in length, spanning over 80kb gnomic 
DNA, encoding a protein o f 3418 aa[10].
Germline mutations in the BRCA2 gene are also associated with approximately 45% 
o f hereditary breast cancer families, but carriers have only a moderately increased risk 
for ovarian cancer [10]. There is an increased risk for developing a number o f other 
cancers, including pancreatic cancer [18, 19], prostate cancer [20], and breast cancer 
in males [21]. Among women who carry germ-line mutations in either o f BRCAl or 
BRCA2 genes, the cumulative risk o f breast cancer is estimated to range from 40% to 
80%, and for ovarian cancer from 5% to 60%, depending on the population from 
which the data were derived [17, 22].
2.5.2.3. FINDINGS ON BRCAl AND BRCA2 FUNCTION
Both BRCAl and BRCA2 contain a region that can act as a transcriptional 
activation domain when it is fused to a DNA binding domain from another gene[23.
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24, 25]. Naturally occurring mutations found in both o f the genes can compromise 
this transcriptional activation.
BRCAl can inhibit the growth o f cells in which it is overexpressed and there is a 
link between an inhibitor of cell-cycle dependent protein kinases and the BRCAl 
protein[26]. Both BRCAl and BRCA2 bind to RadSl which functions in 
maintaining the integrity o f the genome[27, 28]. BRCA2 knock-out mice show 
early embryonic lethality and hypersensitivity to irradiation, similar to that observed 
in the RAD51 knock-out mice[28]. BRCAl knockout mice also show embryonic 
lethality[26, 29]. BRCAl and RadSl proteins share a striking colocalization along 
synaptonemal complexes (junctions between meiotic chromosomes necessary for 
homologous recombination)[28]. It is observed that embryonic and trophoblast 
cells form both BRCA2 and RadSl knockout mice show hypersensitivity to y- 
irradiation[27]. Based on these data it can be inferred that disruption o f a possible 
BRCA/RadS 1 pathway might be expected to lead to genetic instability.
2.5.2.4. POPULATION GENETICS OF BRCAl AND BRCA2
Population geneticists raise some important questions on BRCAl and 
BRCA2[30]. Some o f these are: What proportion o f high-risk families have 
mutations in BRCAl? In BRCA2? How do shared mutations reflect population 
structure ? How frequent are ancient mutations in populations in which they 
arose? What risks are associated with shared mutations ? The answers to these 
questions begin coming
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upon the arrival o f mutation analysis data. The most recent statistics on BRCAl and 
BRCA2 mutations is shown in Table 2-4.
Here are some facts observed upon recent experimental data:
BRCAl and BRCA2 explain 6%-10% o f breast and ovarian cancer cases 
unselected for family history[10]. In Israel this number is higher (15%). In 53 site- 
specific breast cancer families ascertained in United States the frequency of BRCAl 
mutations was twice those o f BRCA2 mutations[31, 32, 33].
The preponderance o f a single BRCA2 mutation in Iceland represents one of the 
most dramatic examples of a founder mutation in isolated populations where 
mutation rate (low), endogamy and isolation (high), and secular trend in penetrance 
all have contributed to the current population structure[34].
In families with male breast cancer, BRCA2 mutations are more common than 
BRCAl mutations. In United States, BRCA2 is responsible for 19% o f familial 
male breast cancers, but for a considerably lower fraction o f male breast cancer in 
the general population[21].
In all regions other than Iceland, the frequency o f BRCAl mutations is 1.5-2.0 fold 
higher than the frequency o f BRCA2 mutations. Lower prevalence o f BRCA2
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mutations in families and patients could be due to fewer mutations, to lower 
penetrance, and/or to later age at onset o f BRCA2 breast cancer[30].
Lifetime risks o f breast cancer associated with BRCAl and BRCA2 are 
approximately equal but that, the age o f onset is later among BRCA2 mutation 
carriers[31].
In the Ashkenazim, two ancestral mutations BRCAl 185delAG and BRCA2 
6174delT each appear in the general population at ~1% frequency and a third 
mutation; BRCAl 5382insC occurs at a population frequency o f 0.11% [35, 36]. 
On the other hand, 52% of the Ashkenazi high-risk breast/ovarian cancer families 
do not carry any o f the recurrent mutations[35, 37, 38]. Whether these families 
carry other novel BRCAl or BRCA2 alleles, have mutations in other, as-yet- 
unidentified susceptibililty loci, or are high risk for nongenetic reasons remains to 
be determined.
The appearance o f the 185delAG mutation embedded in the same haplotype among 
Iranian, Iraqi, and Ashkenazi Jewish families suggest that this mutation predates the 
separation o f these communities from each other at the time of the destruction o f 
the Second Temple in year 70 o f the common era. This mutation is more than 
2,000 years old[37, 38]. The 5382insC mutation was observed in northern and 
eastern families, as well as in Russian , Hungarian and Ashkenazi Jewish
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families[30]. Its high frequency in eastern European populations are consistent 
with a Baltic origin during the medieval period (~38 generations ago)[39],
BRCA2 mutations observed in Japan are unique to that country[40]. The 
distribution o f mutations in other Asian populations is not reported yet.
Table 2-4 BRCAl and BRCA2 mutations of familial breast cancer families.
( Adapted from reference 30).
BRCA1-BRCA2 MUTATIONS OF BREAST/ OVARIAN CANCER FAMILIES
POPULATION
Families with 3 or more 
cases of female breast
and/or ovarian cancer BRCAl % BRCA2 %
Britain 71/339 21% 25/290 9%
Canada 12/30 40% 8/49 16%
Finland 8/100 8%
France 38/160 24% 14/77 18%
Germany 9/49 18%
Holland/Belgium 71/517 14%
Hungary 7/32 22% 4/32 13%
Iceland 1/11 9% 7/J1 64%
Israel 16/34 ‘ 47% 8/34 24%
Italy 21/73 29%
Japan 2/20 10%
Nonway 3/25 12%
Russia 15/19 79%
Sweden/Denmark 24/106 23% 12/106 11%
United States i^/179__ 39% 24/94____ _25%
r .  ...
Families with male
and female breast cancer
I
United States 2/24 8% 12/64 19%
Hungary 0/6 0% 2/6 33%
Iceland b/ib 0% 9/10 90%
Breast and/or ovarian
cancer families not selected
for familiy history
Iceland 42/497 __  8%
Italy 4/49 8%
Israel 23/243 9% 14/243 6%
Japan 8/179 4% 2/103 2%
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The following figures shows the mutation distribution o f BRCAl and BRCA2 
genes with respect to their exons The data is obtained from the Breast Cancer 
Information Core on the Intemet[41] The y-axis gives the number of mutations 
encountered up-to-date.
2.S.2.5. MUTATION STATUS OF BRCAl AM) BRCA2
#  MUTATIONS
EXON NUMBERS
I'icurc 2-1 Mutations of lllW’Al exons. In all the exons except for t and 4 which arc not 
transcribed harbor gcrmlinc mutations which lead to hereditars breast cancer. Due to its large 
size, the most frequently mutated exon is 11.
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y //A  #  MUTATIONS
f-igurc 2-2 IVluta(ion<i of 11R(,’A2 exons. Also in BRCA2 exon ) 1 harbors majorits (43 9%) of 
Ihc gcrnilinc mulahons. In addition exons 9. 10,23 and 24 are frequently nnitaleci
Figures 2-.'^  and 2-4 show the distribution of mutations of BRCAl and BRCA2 
respectively, according to the exons and indicates which exon harbors whal 
percentage of the total mutations
IX
exon 1 1 
4 7 .0 %
rest o f exons 
17.0%
Figure 2-3 Mutation distribution of BRi.’A l. Exons 11. 2. .S. 16 and 20 harbor 8.3% o f the 
BRCAl gcmilinc mutations These exons altogether make up approximately 60'K, o f the total 
transcribed region
3.6%
l igurc 2-4 Mutation distribution of I{R(!A1. Similar to BRCAl. four c.xons -namely 11.0.  10 
and 23- harbor majority (~f>2%) of the BRCA2 mutations.
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Figures 2-5 and 2-6 show the types o f mutations seen on exon 11 of BRCAl and 
BRCA2 respectively. These data are important, since our mutation search is done 
on these exons.
transversion
Figure 2-5 B R C A l exon 11 mutations. Point mutations make up 41% of the stnictural 
aberrations on the exon 11 of BRCAl gene. The rest o f the mutations are small deletions and 
rarely, small insertions.
del 5  
4% del 4
Figure 2-6 BRCA2 exon 11 mutations. The spectnim of BRCAl exon 11 mutations are 
different than the BRCAl c.xon 11 mutations. Transitions and transversions make up 18% of the 
mutations. The rest of the mutations are deletions o f a single or a few base pairs.
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From the data accumulated at the Breast Cancer Informatioii Core on the Internet 
[41], it can be observed that the mutations are spread evenly throughout the 
genome. Approximately 95% o f the mutations are predicted to give rise to 
truncating protein products o f variable size. Because of its larger size exon 11 of 
both o f the genes seem to accumulate the mutations; 47% and 44%, for BRCAl 
and BRCA2 respectively. Founder mutations increase the number o f mutations per 
exon. Exons 2, 5 and 20 harbor such mutations. One o f the most prevalent 
mutations in Ashkenazi Jews, 185delAG mutation, resides in exon 2 o f B RCA l.
If we look at the types o f mutations, single nucleotide substitutions (transversions 
and transitions) prevail in BRCAl; 44% o f all the mutations, while this number is 
slightly lower for BRCA2[41].
2.6. THEORETICAL PRINCIPLES OF THE MUTATION DETECTION
TECHNIQUES
2.6.1. HETERODUPLEX ANALYSIS
Heteroduplex analysis [HA] is one o f the cheapest, easiest and most reliable 
techniques in mutation detection [42J. The PCR amplified fragment is denatured by 
heating and then reannealed by slowly cooling down. So, two complementary 
strands, derived from alleles that differ in sequence, will include mismatched 
positions when base-paired. These mismatched positions will lead to migration 
differences when run on a polyacrylamide gel. Figures 2-7 explains the theory o f 
heteroduplex analysis and figure 2-8 shows an analysis performed in our laboratory.
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HETERODUPLEX ANALYSIS
A normal human being has two copies of a certain gene, 
if one of the alleles has received a mutat ion such as;
GrTTATTGCATT........CTAATAATA
CAAATAACGTAA...... .G ATTATTAT
GTTTTG CATT....... CT A AT A AT A m 1
CAAAACGTTAA.......GATTATTAT m2
Heating denatures the two strands (95®C 5min)
wt1
wt2
A two bp deletion has 
occured, i.e. th e 5t h and 
6th nucleot Ides are 
missing In this allele.
It should be observed that 
wtl Is 100% complementary 
to wt2, and more than 99%  
complementary to m2.
The same Is tr ue for wt2 against 
wt1 and m1.
Locatl on of t he 2b p delet Ion
So cooling down slowly leads to reannealing of the fragments, 
and what is being formed is:
h
o
w tl GTTTATIGCATT........CTAATAATA „
CAAATAAOGTAA......GATTATTAT d
U
 ^ ^  ^  ___GTTTTGCATT.................................... CTAATAATA i*
y>C>0000<i:>O0OQ)i^  ^ 2  CAAAACGTAA......GATTATTAT e
X
e
wt 1 GTTTATtgCATT........CTAATAATA
m2 CAAA ACGTAA........GATTATTAT
wt2 CAAa TAacGTAA... ....GATTATTAT
‘ m1 GTTT TGCATT...,....CTAATAATA
The site where the mismatch occurs 
preventing compiete annelaiing
t
e
r
0 
d 
u
P1
e
X
e
s
Figure 2-7 Heteroduplex analysis. Here is a schematic view of how heteroduplex formation is 
acliieved.
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Figure 2-8 Anatomy of a heteroduplex gel. A; Schematic representation o f the basis of 
heteroduplex analysis is shown. B; The bands form during heteroduplex analysis appear as three 
bands if  there is a mutation (lane 1), one band if  tlie two alleles are completely the same(lane 2) 
in the PAGE gel stained with silver nitrate.
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2.6.2. SINGLE STRAND CONFORMATIONAL POLYMORPHISM
ANALYSIS (SSCP)
Single strand conformational polymorphism (SSCP) analysis, along with HA , is 
one o f the most straightforward, easiest and the cheapest methods o f mutation 
detection [43]. The PCR amplified target sequence is separated as single stranded 
molecules by application o f a denaturing chemical and loaded on a non-denaturing 
gel. This technique relies on the alteration o f the migration pattern o f the strands 
that have any sequence difference. This mobility shift is believed to be caused by 
mutation-induced changes o f tertiary structure o f the single-stranded DNA. The 
technique is schematically explained in figures 2-9 and 2-10.
SSCP
Figure 2-9 Anatomy of an SSCP gel. Due to the differential migration o f single strands, a 
mutation bearing DNA can be differentiated from that o f a non-mutation carrying homozygous 
D N A
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SINGLE STRAND CONFORMATIONAL POLYMORPHISMS rSSCPI
A normal human being has two copies of a certain gene, 
if one of the alleles has received a mutation such as;
X yyO >O O C O iX xr GnTATlGCATT....... CTAATAATA wt 1
CAAATAACGTAA.......GATTATTAT wt 2
.....Y Y T i-Iiili- " IC A A A A C G TA A ..........G A T T A T T A T  m2 6th nucleotides are
missing in this allele.
Heating denatures the two strands
(95^C 5min)
wt 1
It should be observed that 
wt 1 Is 100 % complement ary 
Wt 2 to wt2, and more than 99%
complementary to m2.
The same Is tr ue for wt2 against 
m1 wt1 andm1.
m2
Locatl on of t he 2bp delet ion
We can prevent reannealing so that 
the strands stay in single stranded form
(Putting formamide and rapid cooling on ice)
And they retain a 3-dimensional shape depending on the sequence; 
Even a single base change should be visible on the PAGE gel.
They may migrate differently.
Figure 2-10 SSCP analysis. Here is a schematic view of single strand conformational 
polymorpliisms are induced.
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2.6.3. PROTEIN TRUNCATION TEST
The protein truncation test (PTT) detects mutations that interrupt the reading frames 
o f genes. The technique is based on coupled transcription and translation o f PCR 
products in vitro. The templates for PTT are generated by PCR either from reverse 
transcribed RNA or directly from genomic DNA. During PCR, a 36-base pair 
extension, encoding the bacteriophage T7 promoter sequences as well as an 
eukaryotic translation initiation signal, is added to that end o f the PCR-product 
which correspods to the amino terminus. Simultaneous transcription and translation 
o f amplification products is performed in a rabbit reticulocyte lysate system using 
radiolabeled aminoacids. Translation products are subsequently resolved by SDS- 
PAGE and detected by autoradiography[43, 44]. Figure 2-11 depicts the basis o f a 
PTT reaction.
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1
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<tLi0 lo t hn mutat ion
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Figure 2-11 PTT. Tills is a schematic view o f how mutations leading to truncated products are 
revealed.
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2.6.4. CHEMICAL MISMATCH CLEAVAGE
The chemical mismatch cleavage is a technique for detecting and localizing 
mismatches in heteroduplex DNA molecules[42, 45]. It relies on the chemical 
reactivity o f mismatched C and T bases to hydroxylamine and osmium tetroxide, 
respectively. Once reacted, the DNA strands are cleaved at the reacted mismatched 
base by piperidine and the molecules are separated by size to identify the location o f 
the mismatched positions.
2.6.5. DIRECT SEQUENCING
In today’s technology, it is the only technique that is capable o f finding out 100% 
o f the mutations. However, its high cost and arduous labor-requirement brings it 
among the rarely utilized techniques for mutation detection. On the other hand, it is 
an obligation to sequence, when a mutation is encountered by the indirect mutation 
detection techniques. It is the only means to identify the mutation and locate it 
precisely.
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The aim o f this thesis is establishment o f a rapid mutation detection technique for 
the investigation o f the two breast cancer susceptibility genes BRCAl and BRCA2. 
Heteroduplex analysis is chosen to be the most suitable technique, which is 
accurate, rapid and cheap. Upon establishment o f this technique, 15 Turkish familial 
breast cancer patients are screened for BRCAl and BRCA2 mutations. Since the 
genes are too large (BRCAl requires 40 pairs, BRCA2 requires 44 pairs o f primers 
for entire screening.), we first chose the exons which harbor most o f the 
documented mutations to establish the technique. To screen BRCAl, primers for 
exon 11, as well as primers flanking exons 5, 13 and 20 have been synthesized. One 
o f the most frequently seen mutations 5382insC resides in exon 20. To screen 
BRC A2, primers spanning the first half o f exon 11 have been synthesized (16 pairs 
span the whole exon, while we have synthesized the first 8).
The results o f this study will help us to develop a non-readioactive indirect mutation 
screening technique, which can be used to characterize the mutations in BRCAl 
and BRCA2 genes in the Turkish population. Subsequently, genetic counselling for 
the high risk individuals can be offered and insight into the population genetics o f 
hereditary breast cancer can be obtained.
2.7. AIM
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3. MATERIALS AND METHODS
3.1. MATERIALS
3.1.1. THE BIOLOGICAL MATERIAL
3.1. LLMUTATION CARRYING DNA
Four mutation carrying DNA samples which were characterized previously[46], 
belonging to French familial breast cancer patients on BRCAl that have been 
donated us kindly by Dr. Gilbert Lenoir, was used for the establishment o f the 
heteroduplex analysis technique in our laboratory. These DNA samples serve as 
positive controls to check the efficiency o f the mutation detection techniques.
Table 3-1 The mutation carrying DNA.
THE MUTATION CARRYING DNAs
No.
2638
Mutation
nt279J
Gene Primer pairs
893del4 B BRCA1
I
GA 23-24
2944 908G-T nt2841 BRCA1 GA 23-24
3300 1160del11 nt3599 BRCAl GA 31-32
2651 Ï234del5 nt3819 BRCA1 GA 33-34
.30
3.I.I.2. DNA OF TURKISH BREAST CANCER PATIENTS
Blood samples have been obtained from 22 breast cancer patients in collaboration 
with Hacettepe University, Istanbul University and Ankara Oncology Hospital. The 
list o f the Turkish breast cancer patients that have been studied is shown in 
Table 3-2.:
Table 3-2 List of the Turkish familial breast cancer patients. 
PATIENT LIST
FAMILY
CODE
DNA
CODE
AGE OF 
DIAGN.
DEPT.
OBTAINED
DR.
BRC-1 96-1 45 Capa Medical Fac. Dr.Mahmut Muslumanoglu
BRC-2 96-2 25 Capa Medical Fac. Dr.Mahmut Muslumanoglu
BRC-3 96-3 50 Capa Medical Fac. Dr.Mahmut Muslumanoglu
BRC-4 96-4 50 Capa Medical Fac. Dr.Mahmut Muslumanoglu
BRC-5 96-5 33 Capa Medical Fac. Dr.Mahmut Muslumanoglu
BRC-6 96-6 51 Capa Medical Fac. Dr.Mahmut Muslumanoglu
BRC-6 96-7 33 Capa Medical Fac. Dr.Mahmut Muslumanoglu
BRC-7 96-8 37 Capa Medical Fac. Dr.Mahmat Muslumanoglu
BRC-7 96-9' Capa Medical Fac. Dr.Mahmut Muslumanoglu
BRC-8 96-10 4S "У  0/ Capa Medical Fac. Dr.Mahmut Muslumanoglu
BRC-9 97-114 34 Hacettepe Med. Fac. Dr. Mesut Tez
BRC-10 97-137 32 Oncology Hospital Dr.Oguz Tarcan
BRC-11 97-270 29 Oncology Hospital Dr.Oguz Tarcan
BRC-12 97-274 40 Hacettepe Med. Fac. Dr. Mesut Tez
BRC-13 97-343 35 Oncology Hospital Dr.Oguz Tarcan
' This patient is not a breast cancer patient, but a member seeking genetic counseling.
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The families are grouped according to the criteria for the familial breast cancer 
cases[46]. Group 1 is the ‘breast cancer-only’ cases (be) where there is at least two 
breast cancer cases with one o f them either bilateral breast cancer or early onset 
(before age 40). The families are B R C l, BRC2, BRC3, BRC4, BRC6, BRC7, 
BRCIO. Group 2 is the familial breast/ovarían cancer cases (b/o), where at least 
three breast or ovarian cancer cases are present among the first or second degree 
relatives.The family is BRC8. Group 3 consists o f cases that are classified as 
sporadic. The families are BRC5, BRC9, B R C ll and B R C l2. Finally, group 4, 
which has only one family (BRC13), denotes the cases whose pedigrees could not 
be obtained. Family BRC13. Table 3-3 is the list o f the families we have obtained 
and grouped as mentioned. The pedigrees are given in the appendix.
3.1.2. PEDIGREES
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Family Patient(s) t! patients 
in family
Indication Group
BRC-1 96-1 6 3 be Patients 1
BRC-2 96-2 2 2 be cases, in first degree 
relatives
1
BRC-3 96-3 2 2 be cases, one is early onset. 1
BRC-4 96-4 2 2 be cases, one is early onset. 1
BRC-5 96-5 2 2 be cases, one early onset, 
but in second degree relatives
BRC-6 96-6/96-7 2 be cases, one is early onset. 1
BRC-7 96-8/96-9- 2 2 be cases, one early onset, 
one is a male breast cancer case.
1
BRC-8 96-10 4 One be case with 2 b/o and 
one be case in second degree 
relatives
2
BRC-9 97-114 1 One be case of early onset
BRC-IO 97-137 4 3 be cases in first degree, 
one be case in second degree 
relatives
1
BRC-Il 97-270 2 One early onset be case with 
one be case in second degree 
relatives.
BRC-12 97-274 1 One early onset be case.
BRC-13 97-343 7 No data available 4
J ahic 3-3 Hrcflsl cancer lamilics.
Fliis individu;il is nol:» brcasl cancer patient, but a person seeking* genetic counseling
3.1.3. CHEMICALS
Absolute ethanol (JDEl-Delta) 
Acetic acid (A6283-Sigma) 
Acrylamide (A9099-Sigma)
Agarose (A9539-Sigma)
APS (420627-Carlo Erba) 
Bisacrylamide(M2022-Sigma)
Boric Acid (B6768-Sigma) 
Bromophenol blue (B5525-Sigma) 
Chloroform (438603-Carlo Erba) 
dNTP mix (A4916-Sigma)
EDTA (SE5134-Sigma)
Ethidium bromide (SE7637-Sigma) 
Ficoll (F4345-Sigma)
Formaldehyde (F8775-Sigma) 
Formamide (F7508-Sigma)
Isoamyl alcohol (413836Carlo Erba) 
NaOH (S0899-Sigma)
Parafilm (Can-Sigma)
Phenol (P1037-Sigma) 
Silvernitrate-AgN03-(S8157-Sigma)
Sodium acetate (366207-Carlo Erba) 
Sodium Citrate (368007-Carlo Erba) 
Size markers :
lOObp DNA ladder (G2101-Prome) 
OX174DNA/Hinf I (G1751-Prome) 
ADNA/EcoRI+HindIII(G 1731 Pro) 
TEMED (ST8133-Sigma)
Tris Hcl (ST3253-Sigma)
Xylene cyanol (X4126-Sigma)
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5xPCR buffer ( Supplied with Taq polymerase)
10 X TBE buffer ( lit - 108gr Tris, 55gr Boric Acid, 0.3gr EDTA-pH 8.3 ) 
Non-denaturing polyacrylamide gel
( 50ml - 7.5 ml from 40% 39; 1 Acrylamide;bisacrylamide solution, 5ml lOXTBE, 
350ul 10%stock o f APS, 37 .15ml ddH20 and just before pouring 40ul TEMED.)
Silver staining solutions:
* All the solutions should be prepared with deionized H2O.
Fixing solution (600ml-Aqueous solution o f 10%(v/v) ethanol, 0.5%(v/v) acetic 
acid.)
Staining solution (300ml -0.1% aqueous solution o f silver nitrate (AgNOs)). 
Developer solution (500ml -Aqueous solution o f J.5%  (w/v) NaOH,
0. l%(v/v) formaldehyde. Must be prepared immediately before use.)
Protecting solution (300ml - 7.5% (v/v) aqueous solution o f acetic acid.)
3.1.4. SOLUTIONS
3.1.5. ENZYMES
Taq polymerases:
AmpliTaq Gold (NN808-0241 Perkin Elmer)
Taq Polymerase (1 146173-Boehringer Manheim) 
Proteinase K (161519- Boehringer Manheim)
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3.1.6. PRIMERS
3.I.6.I. PRI.VIERS FOR BRCAl
CODE r n m  From 5· to 3·
BRCAl exon 11 AA GA 1 GGAATTAAATGAAAGAGTATGAG
BRCAl exon 11 AA GA 2 CTAAGCCAGGCTGTTTGCTT
BRCAl exon 11 BB GA 3 ACAGCATGAGAACAGCAGTTT
BRCAl exon 11 BB GA 4 CTCTAGGATTCTCTGAGCATTG
BRCAl exon 11 CC GAS GGTAGATCTCGAATGCTGATCCC
BRCAl exon 11 CC GA6 GCCTCATGAGGATCACTGG
BRCAl exon 11 DD GA 7 GCCAAAGTAGCTGATGTATTGG
BRCAl exon 11 DD GAS CGCTTTAATTTATTTGTGAGGG
BRCAl exon 11 EE GA 9 CCCAACTTAAGCCATGTAACTG
BRCAl exon 11 EE GA 10 ATTCATCACTTGACCATTCTGA
BRCAl exon 11 FF GA11 ATTTGGCAGTTCAAAAGACTCC
BRCAl exon 11 FF GA 12 TTTAGGTGCTTTTGAATTGTGG
BRCAl exon 11 GG GA 13 AAAGCTGAACCTATAAGCAGCA
BRCAl exon 11 GG GA 14 GTTTCTGCTGTGCCTGACTG
BRCAl exon 11 HH GA 15 GCCCACCTAATTGTACTGAATT
BRCAl exon 11 HH GA 16 CTTGGAAGGCTAGGATTGACA
BRCAl exon 11 JJ GA17 TGAAGTTAACAAATGCACCTGG
BRCAl exon 11 JJ GA18 ACGAGATACTTTCCTGAGTGCC
BRCAl exon 11 KK GA 19 GGGTTTTGCAAACTGAAAGA
BRCAl exon 11 KK GA 20 CTTGTTTCCCGACTGTGGTT
BRCAl exon 11 LL GA 21 GGGACTAATTCATGGTTGTTCC
BRCAl exon 11 LL GA 22 TTTCTTTAAGGACCCAGAGTGG
BRCAl exon 11 MM GA 23 TTTGCTCCGTTTTCAAATCC
BRCAl exon 11 MM GA 24 TCGTTGCCTCTGAACTGAGA
BRCAl exon 11 NN GA 25 GATAAGCCAGTTGATAATGCCA
BRCAl exon 11 NN GA 26 CGGCTAATTGTGCTCACTGT
BRCAl exon 11 OO GA27 TTGAGGAACATTCAATGTCACC
BRCAl exon 11 0 0  GA28 ACCTCAGGTTGCAAAACCC
BRCAl exon 11 PP GA 29 CCAGTGATGAAAACATTCAAGC
BRCAl exon 11 PP GA 30 TTCACCATCATCTAACAGGTCA
BRCAl exon 11 RR GA 31 AACTTAGAACAGCCTATGGGTT
BRCAl exon 11 RR GA 32 AACAAGTGTTGGAAGCAGGG
BRCAl exon 11 SS GA 33 AGGGGCCAAGAAATTAGAGTC
BRCAl exon 11 SS GA 34 CTTCCAATTCACTGCACTGTG
BRCAl exon 11 TT GA35 AAAGGCATCTCAGGAACATCA
BRCAl exon 11 TT GA 36 CAAAAACCTGGTTCCAAGAC
BRCAl exon 2 QQ GA 47 AAACCTTCCAAATCTTCAAA
BRCAl exon 2 QQ GA 48 GTCTTTTCTTCCCTAGTATGT
BRCAl exon 5 WW GA 50 GCTCTTAAGGGCAGTTGTGA
BRCA1 exon 5 WW GA 52 ATAGCGTTCCTATAAAACCATT
BRCAl exon 13 YY GA 53 AATGGAAAGCTTCTCAAAGTA
BRCAl exon 13 YY GA 54 TGTTGGAGCTAGGTCCTTAC
BRCAl exon 20 ZZ GA 55 ATATGACGTGTCTGCTCCAC
BRCAl exon 20 ZZ GA 56 AGTCTTACAAAATGAAGCGG
3.1.6.2. PRIMER.S FOR BRCA2
BRCA2
BRCA2
BRCA2
BRCA2
BRCA2
BRCA2
BRCA2
BRCA2
BRCA2
BRCA2
BRCA2
BRCA2
BRCA2
BRCA2
BRCA2
BRCA2
exon
exon
exon
exon
exon
exon
exon
exon
exon
exon
exon
exon
exon
exon
exon
exon
11
11
11
11
11
11
11
11
11
11
11
11
11
11
11
11
A
A
B
B
c
c
D
D
E
E
F
F
G
G
H
H
From 5' to 3’
GA 58 GATTGATGGTACTTTAATTTTGTCAC
GA 59 GCCAAGACCTCTTCTTTTATATCTG
GA60 AAGCTGATTCTCTGTCATGCCTG 
GA 61 GATTTGTGTTTTGGTTGAATTGTACC
GA 62 CGTTGAGCTGTTGCCACCTG
GA 63 CCTCCAAAACTGTGATTTGAAATTG
GA 64 TTGGTTTATGTTCTTGACGAGGAG
GA 65 CCTTTTGGCTAGGTGTTAAATTATGG
GA 66 TGGCA7TAGATAATCAAAAGAAACTG
GA 67 CCTAAACCCCACTTCATTTTCATC
GA 68 GAAATTAAACGGAAGTTTGCTGG
GA 69 TGAATCACTGCCATCAAATTCTAAG
GA 70 AATGACTACTGGCAC I I I IGTTG
GA 71 CACTTGCAGTCTGAAAAAATGTATC
GA 72 TGCGAAAGCTCAAGAAGCATG
GA 73 TGATGGCTAAAACTGGTGATTTCAC
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3.2. METHODS
3.2.1. DNA EXTRACTION FROM BLOOD
The blood obtained from the patients are aliquotted as 700pl samples into 1.5ml 
eppendorf tubes and frozen by putting them to -80°C. Upon thawing the blood, 
800|.il o f IxSSC buffer is added to wash the cells and the contents spinned 1 min in 
the centrifuge at 13000rpm. The supernatant is removed and discarded. This 
washing with SSC step is performed until the pellet becomes close to white in 
color. To the pellet 400|.il extraction buffer and 5 pi proteinase K (20mg/ml in H 20) 
is added and incubated at 56°C for overnight. The next day 120ml 
phenol/chloroform/isoamyl alcohol mixture was added onto the ingredients o f the 
tube and vortexed briefly. Then 2 minutes centrifugation at 13000rpm is performed. 
The upper aqueous layer is removed avoiding the interface and placed in a new 
1.5ml eppendorf tube. These steps including the 2 minutes centrifugation is 
repeated several times. 35pl 3.0M sodium acetate pH2.0 and 700pl cold absolute 
ethanol is added onto the pellet. The tube is placed at -20°C for a minimum o f 15 
minutes. Centrifugation at 13000rpm is performed and the alcohol is removed by 
decantation. The pellet is washed with 1.0ml 70% room temperature ethanol. Then 
5 minutes centrifugation for 5 minutes at 13000rpm should prevail. The supernatant 
is decanted and the remaining alcohol is removed by a micropipette. To eliminate 
completely the alcohol, the eppendorf tubes are centrifuged at a hetovac centrifuge 
for 10 minutes. Finally the DNA is resolubilized in 200pl TE buffer solution for 
overnight and placed at -20“C for further use. The concentration is determined by
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the optical density read by the spectrophotometer at 260nm and 280nm , and 
adjusted to SOng/pl.
3.2.2. AMPLIFICATION BY PCR AND THE TEST GEL
PCR is one o f the most powerful and widely utilized techniques o f molecular 
biology that enables the user to amplify a single copy o f a desired sequence o f DNA 
more than a billion times in a couple o f hours[47]. The requirements for a PCR 
reaction is shown in Table 3-4;
Table 3-4 P (’R ingredients
Template DNA -Total DNA isolated from any organism 
Primers -Two short DNA sequences o f around 20bp that borders the 
sequence to be amplified.
Taq DNA Polymerase- The enzyme which synthesizes DNA and can
work at very high temperatures.
dNTP mixture -The raw material o f DNA comprised o f the four 
nucleotides A,T,G and C
PCR buffer -A buffer in which the enzyme works most efficiently.
Sterile deionized HiO- To increase and provide a volume for the reaction
The ingredients are put in an eppendorf tube by using a micropipette. This 
procedure should be carried out in a UV-sterilized chamber. The theory is as 
follows:
The entire DNA sequence in the tube is first denatured into single strands by the 
increasing temperature, and then each strand is annealed to a different primer. The 
primers are synthetic oligonucleotides complementary to sequences bordering the 
region to be amplified. Taq DNA polymerase is present along with nucleotides to 
extend the primers in the 3 ’ direction (this enzyme can only synthesize in the 5’ to
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incorporated into the newly synthesized strand. In a second PCR cycle, the 
products o f the first cycle are denaturated into single strands, primers are added, 
and they are annealed and extended by Taq DNA polymerase. Repeated cycles can 
amplify the desired DNA sequence which can change from 50 to 1500 nucleotides 
by more than a billion times. One o f the important elements is the PCR machine 
which increases and decreases the temperature at indicated times so that the DNA 
strands are denatured into single strands (95‘'C), the primers are let to anneal (this 
temperature depends on the nucleotide content o f the primer and varies form 50“C 
to 70°C) and the DNA polymerization is performed (72°C). A schematic view o f a 
PCR reaction is as shown in figure 3-1 . I t  is important to test the presence o f the 
desired DNA fragments. For the safety o f the future experiments in which these 
amplified products will be used, the amplification o f only the desired DNA 
fragments should be assured. For this purpose, an agarose gel is prepared which is a 
matrix from which DNA molecules pass and get separated due to their size. In this 
gel ethidium bromide is added which intercalates into the DNA molecule, thereby 
enabling us to see the DNA bands under UV light exposure.
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INSIDE THE TUBE CYCLE 1 TEMPERATURE
T i r n i l  
1 1 1 1 1 1
n i l  1 1 1 
1 1 1 1 1 1
1
5’ r r r i  r n  I I I I I 13’
3’ .I-U.-U-I-I..U
Unamplified DNA Room temperature
Denatured DNA 95“C
11I II I m ’
I I I I I I I I I
Primers anneal . 50“C-70"C
A certain temp 
between these values.
T T T n
I I I I I I I I I
.1.1 U .I I I I I
I I II r u n
1
Taq polymerase 
extends the primers 
in 5’ to 3’ direction.
Complementary strands 
are syndiesized which 
will act as templates 
in the next cycle.
CYCLE2
Dénaturation
and
Annealing
72“C
95 T
5 0 X - 7 0 T  
72 “CPrimer extension and 
repeat of cycle 2
30 times 30x(95T /50-70T /72T ) 
which will yield
2 ^  times
amplification of the 
desired region.
Figure 3-1 A PC R  reaction A schematic view of a PCR reaction.
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a power supply. A size marker is loaded on the gel near the DNA samples to give 
an idea about the size o f the fragments that are present. Then the gel is examined 
under UV-light for the presence o f the desired fragments, and the gel is 
photographed for future reference.
The PCR reaction is set up in 50|al aqueous medium containing 50ng o f genomic 
DNA, 5|.il 5xPCR buffer, lOpl dNTP mix (50pM  from each nucleotide), 25nM 
from each primer and 1 unit o f Taq polymerase. The reactions are performed in the 
PCR machine Perkin Elmer (model 9600) according to the following program: 5 
min. at 95°C, 30 cycles (30sec at 95°C, 30 sec at the annealing temperature o f the 
primer, 30 sec at 72°C) followed by 5 min at 72°C. For each reaction o f PCR, a 
negative control reaction is performed containing all the elements except the 
template DNA. The products o f amplification are controlled by agarose gel 
electrophoresis containing 1.5% agarose in IxTBE buffer (Tris borate 90mM, 
EDTA 2mM) and l|j,l Ethidium bromide. Visualization in performed under UV 
lamp before photographing.
21 pairs o f primers for BRCAl and 8 pairs o f primers for BRCA2 are synthesized 
by our oligosynthesizer in order to amplify the desired regions o f these genes .
Primers are designed to amplify the following regions shown in figure3-2.
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4 4 2  bp
Figure 3-2 The amplified regions of B R C A l. The code numbers of the fragments are given as 
two capital letters, the codes of the primers are written in green boxes. The lengths and locations 
of the French mutation bearing DNa are also included.
BRCA 2
Figure 3-3 The amplified regions of BRCA2. The code niunbers o f the fragments are given in 
purple boxes, codes o f the primers are given in yellow boxes. Length o f the desired PCR product 
is written on the DNA fragments designated as red.
43
3.2.3. POLYACRYLAMIDE GEL ELECTROPHORESIS
Polyacrylamide gel electrophoresis is one o f the most widely utilized techniques in 
molecular biology to separate DNA fragments o f different size and shape. The 
technique relies on the chemically produced matrix, from the pores o f which DNA 
molecules can pass upon application o f an electric current. DNA fragments having 
a few base pair difference can be identified by this method [47]. The chemistry o f 
the gel is as follows:
A chain reaction is initiated in which monomers o f acrylamide are polymerized into 
long chains in the presence o f free radicals supplied by ammonium persulfate and 
stabilized by TEMED. When bisacrylamide is included in the polymerization 
reaction, the chains are cross-linked to form a gel, whose porosity is determined by 
the length o f the chains that are proportional to the concentration o f 
polyacrylamide, and the degree o f cross-linking. The contents o f the gel are poured 
between two glass plates separated by spacers. The glasses containing the gel are 
placed in a tank in which a buffer that maintains the conductance is present. The 
samples are loaded on the gel, together with loading buffer which enables us to 
follow the approximate migration o f the DNA fragments. Then the apparatus is 
connected to a power supply and a certain amount o f electric current ranging 
between TOvolts to lOOvolts is applied. After the run time is finished, the gel is 
mildly removed from the glass plates and dipped into the solutions o f silver staining, 
where gentle shaking is provided by a shaker. Then, the gel is stained by the action
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of the chemicals supplied. The bands can be analysed under an illuminator, and then 
xeroxcopied for future reference.
3.2.4. HETERODUPLEX ANALYSIS
After the PCR amplification, depending on the darkness o f the band on the agarose 
gel film, 1-3 pi o f sample from the amplification tube is transferred to a new 
eppendorf tube onto which 6pl IxTBE buffer is added. This tube is incubated in 
95°C for 5 minutes in a heat block for dénaturation o f the strands and left to cool 
down slowly to 37°C in the heater which takes about 3 hours where the DNA is let 
reanneal. Then lOpl loading dye (15% Ficoll, 0.025% bromophenol blue, 0.025 
%xylene cyanol in water) is added in the tube and loaded to a 20 cm x 20 cm 
vertical non-denaturing polyacrylamide gel (6% w/v 39:1 acrylamide 
bisacrylamide mixture, 5 ml 10 x TBE, 350 pi APS from 10% stock, 37.15 ml 
ddH20 and finally just before pouring , 40 pi TEMED). To confirm the size 25 ng 
o f a size fragment is as well loaded on the gel. Migration is performed in 3 liters o f 
1 X TBE buffer 7-8 hours at 3W or 80V[42].
3.2.5. SINGLE STRAND CONFORMATIONAL POLYMORPHISM
ANALYSIS
This protocol is similar to the heteroduplex analysis. 1-3 pi o f sample from the PCR 
tube is transferred to a new eppendorf tube which contains lOpl o f stop solution 
(95% formamide, lOmM NaOH, 0.025% bromophenol blue and 0.025% xylene 
cyanol). DNA is denatured in this solution by waiting 5 minutes at 95"C.
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Then the sample is immediately placed in ice for a rapid cooling so that the strands 
remain in a single stranded form where it should be waited for at least 20 minutes. 
Then the same procedure should be proceeded where the sample is loaded to a 20 
cm X 20 cm 6 %  non-denaturing polyacrylamide gel and run for 7-8 hours at a 
constant power o f 3W in IxTBE. The gel is stained by silver staining protocol 
described at the following section. In addition, 25ng size marker is loaded to 
confirm the size o f the fragment[43].
3.2.6. SILVER STAINING OF THE POLYACRYLAMIDE GELS
The bands are then visualized by silver staining which is performed as follows: 
After splitting the gel plates, the gel is transferred to a plastic tray lull o f deionized 
water, then without waiting long, the gel is fixed by immersing in an aqueous 
solution o f %10 (v/v) ethanol, 0.5% (v/v) acetic acid for three minutes and this 
step is performed two times. The gel is then washed with deionized H2O and 
transferred to 0.1% aqueous solution o f silver nitrate (AgNOs) where it waits for 
10 minutes. Again washing thoroughly and transferring to an aqueous solution o f 
1.5% (w/v) NaOH, 0.1% formaldehyde which is prepared immediately before use. 
The staining takes place in this step and we wait until the bands are visible which 
varies between 20-35 minutes. The gel is washed and kept in 7.5% (v/v) aqueous 
solution o f acetic acid until transferring between two transparent films and 
xeroxcopying. It should be noted here that all the solutions in silver staining 
protocol should be prepared using deionized distilled water. The gel can be dried 
at a gel dryer or simply discarded.
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4. RESULTS
4.1. PCR
PCR is performed in order to amplify the desired fragments o f BRCAl and 
BRCA2 genes on which heteroduplex analysis would be done. Figure 4-1 is a 
test-gel film o f PCR products.
1 2 3 4 5
Figure 4-1 Test gel. Result o f a 
PCR reaction. Using one pair of 
primer (GA 72-73), H fragment of 
BRCA2 has been amplified in 
four patients. The expected size is 
510bp which is proven by the 
0 X 1 7 4  size marker (lane 1). 
Lanes 2, 3, 4 and 5 are the 
amplified fragments o f patients 
96/1, 96/2, 96/3 and 96/4
respectively. Lane 6 is the 
negative control which proves 
that no contamination has 
occurred.
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The efficiency o f the rapid mutation detection techniques is determined by using 
positive controls. The controls include four mutation carrying DNA samples 
obtained from French breast cancer patients and donated kindly to us by Dr.Gilbert 
Lenoir. The location and type o f mutations were already known. We used these 
samples to optimize our techniques. Table 4-1 lists the mutation carrying DNA 
samples and whether the mutations could be detected in our hands or not
Table 4-1 Mutation carrying DNA.
4.2. EFFICIENCY OF THE TECHNIQUES
No. Mutation Gene Mutation detected by 
SSCP HA
2638 893del4 nt2798 BRCA1 yes yes
2944 908G-T nt2841 BRCA1 no no
3300 1160del11 nt3599 BRCA1 yes yes
2651 1234del5 nt3819 BRCA1 yes yes
O f the four positive control DNA samples, three small deletions could be identified 
(patients 2638, 3300 and 2651), however we were unable to detect the point 
mutation, which is a transversion form guanine to thymine (patient 2944). The gel 
pictures at figure 4-2 and 4-3 are evidences to how we have shown the mutations o f 
patients 2638 and 2651. The 11-base pair deletion (patient 3300), which was clearly 
visible on the gel, is not shown here.
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Figure 4-2 Verification o f  the heteroduplex analysis technique. Lanes 1 and 6 
are both the known four base pair deletion mutant (patient 2638). Appearance of 
three bands indicate the presence o f a mutation. Lane 2 is the sample
which has no mutation. Lanes 3,4 and 5 contain the transversion mutation G-T 
(patient 2944), that we couldn’t demonstrate in this gel.
Figure 4-3 Heteroduplex analysis of control DNA. In lane 1 a five 
base-pair deletion (patient 2651) vvith its control at the adjacent lane, 
and in lane 4, a four base-pair deletion (patient 2638) with its control 
at the third lane are present. Note that, 1 base-pair difference between 
the fragments at lanes 1 and 4 lead to a completely different migration 
pattern o f their
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4.3. MUTATION SEARCH OF THE PATIENTS
4.3.1 BRCAl
After verifying the efficiency o f the heteroduplex analysis technique, we proceeded 
to search for the mutations o f the 15 Turkish breast cancer patients. For BRCAl, 
entire exon 11 which is spanned by 18 pairs o f primers and three additional exons; 
exons 5, 13 and 20 where the mutations mostly occur, have been screened. 
However, no evidence o f a mutation, ie. Altered size fragments on polyacrilamide 
gels, was found. Figure 4-4 is a gel example to which the rest o f the results are 
similar.
564bp
K K l KK2 KK3 KK4 KK5 S.M
Figure 4-4 Heteroduplex analysis of 
B R C A l fragments. The first five 
lanes are the same region o f BRCAl 
gene in 5 different patients .The 
patients are 97-114, 97-137, 97-270, 
97-274 and 97-343; in lanes 1, 2, 3, 4 
and 5 respectively. And the fragment 
is the KK fragment o f BRCAl. The 
bands comigrate and thus, don’t 
indicate a mutation. As a size marker 
Lambda DNA/EcoRl+Hindlll digest is 
loaded to the last lane
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4.3.2, BRCA2
Part o f the BRCA2 exon 11 has been screened for mutations by heteroduplex 
analysis. Normally we have designed 16 pairs o f primers that span the entire exon, 
however for the beginning we have used eight pairs o f these primers to screen 10 
Turkish breast cancer patients. The results indicate no mutations in the region o f
interest.
8 10 11 12 13 14
+cont AA7 AA8 AA9 AAl SM BBl BB2 BB3 BB4 BBS BB6 BB7 BBS
Figure 4-5 Heteroduplex analysis o f  patients for BRCA2. Screening o f two different fragments 
in the BRCA2 gene exon 11 is shown in this figure. 345bp is the size o f the first five fragments, 
while 462bp is the size o f  the rest o f  the fragments.4>X174 is loaded to lane 6 as the size 
marker.No mutation is visible in this gel. The two letters AA and BB are the codes o f  the 
exonl 1 fragments and the number indicates the patient. For example, A A l is the first fragment 
form the 5 ’ end o f  exon 11 o f  the patient 96/1 and BB7 is the seventh fragment form the 5 ’ end 
o f exonl 1 o f  the patient 96/7.
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In 10 Turkish breast cancer patients no mutations are encountered at approximately 
half of exon 11. Table 4-2 summarizes our studies.
Table 4-2 Summary of
Gene
BRCA1
BRCA1
BRCA1
BRCA1
BRCA1
BRCA1
BRCA1
BRCA1
BRCA1
BRCA1
BRCA1
BRCA1
BRCA1
BRCA1
BRCA1
BRCA1
BRCA1
BRCA1
BRCA1
BRCA1
BRCA1
exon
exon 11 
exon 11 
exon 11 
exon 11 
exon 11 
exon 11 
exon 11 
exon 11 
exon 11 
exon 11 
exon 11 
exon 11 
exon 11 
exon 11 
exon 11 
exon 11 
exon 11 
exon 11 
exon 5 
exon 13 
exon 20
our mutation search in BR C A l and BRCA2.
mutation detected?
no
code
AA
BB
CC
DD
no
no
no
EE no
m ut?FF no Gene exon code
GG no BRCA2 exon 11 A no
HH no BRCA2 exon 11 B no
JJ no BRCA2 exon 11 C no
KK no BRCA2 exon 11 D no
LL no BRCA2 exon 11 E no
MM no BRCA2 exon 11 F no
NN no BRCA2 exon 11 G no
OO no BRCA2 exon 11 H no
PP no
RR no
SS no
TT no
WW no
YY no
ZZ no
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DISCUSSION
The aim o f this thesis is to establish a rapid mutation detection technique for the 
analysis o f the genes BRCAl and BRCA2. Therefore a cheap and a fast technique, 
heteroduplex analysis (HA), has been established in our lab. The superiority o f HA 
over other mutation detection techniques such as SSCP was proven in recent 
studies[48]. Even though the two techniques work in a similar efficiency (detecting 
100% o f the small deletions but not o f the point mutation tested), HA seems to be 
more suitable for our laboratory. SSCP is also a powerful technique, but it seems 
that it should be combined with radioactive labelling which leads to the observation 
o f sharper bands than silver staining. Our inability to detect the point mutation 
(patient 2944) is a pitfall since about 40% o f the mutations occurring in BRCAl 
and BRCA2 are indeed point mutations. Nevertheless, we need to study more 
patients, since the only documented case with a point mutation in our study group 
was the French patient mentioned in Table 4-1. Therefore, deciding upon a single 
sample may be too harsh, since studies show that HA misses only 13,5% o f the 
point mutations.
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Based on these considerations, the technique we applied appears to be powerful 
enough to be utilized for initial mutation screening.
Our next step was utilizing this technique, to screen for mutations in Turkish breast 
cancer families. We have obtained blood from 15 families. O f these, seven are 
diagnosed as breast cancer and one o f them is a breast/ovarian cancer family, four 
o f the families do not meet any criteria to be classified as inheriting mutations, thus 
these patients are classified as sporadic cases and for one family we don’t have 
pedigree data. We have screened the entire exon 11 o f BRCAl gene which is about 
50% o f the coding region and half o f exon 11 o f BRCA2 gene which constitute 
about 25% o f the coding region .As a result we couldn’t encounter any mutations. 
From these results three deductions can be made:
* The mutations are found elsewhere in the genome.
* Mutations were present but they were the type we were unable to detect (point 
mutations).
* Mutations might be at the non-coding regions.
* The cause o f familial breast cancer in Turkey is not the BRCAl and BRCA2 
genes but other genes which are yet to be found.
* The cases were not familial.
54
The world-wide breast cancers attributed to BRCAl and BRCA2 is between 6%- 
10% o f all the breast cancer cases including sporadic forms. Regarding this fact at 
least one mutation should be lying in DNA o f the patients we have. Upon searching 
the entire coding regions it is expected that we will be able to find out a mutation.
At this point we do not have enough data to put the association o f BRCAl and 
BRCA2 genes with breast cancer o f Turkish patients among the world statistics, 
however upon accumulating our data and using additional mutation detection 
techniques like PTT and sequencing, we will be able to give information about the 
Turkish population. Besides we will be able to find the presence o f founder 
mutations in the Turkish population.
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APPENDIX A
PEDIGREE SYMBOLS
A breast cancer pat ient 
woman
A woman deceased due to 
breast cancer
Patient code
/ Birth date(Year of onset of breast cancer) 
(Any additional information)
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to give information about 
the index.
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